CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
Endovascular Stent-graft repair of descending thoracic aortadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00757003
NCT00757003Phase 3Completed

A Clinical Study of the TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Diseases for Non-Surgical Candidates Under the Physician Sponsored IDE.

Stanford University·interventional·Posted Sep 22, 2008·Updated Mar 1, 2017

In Brief

A Phase 3 clinical trial evaluating Endovascular Stent-graft repair of descending thoracic aorta for Aneurysm, Dissecting and Aortic Aneurysm, Thoracic. Completed, enrolled 100 participants across 1 site.

Detailed Summary

PURPOSE OF RESEARCH: Endovascular stent-graft repair of aortic pathologies is a minimally-invasive alternative to open surgery that may decrease morbidity and mortality, particularly in high risk patients. Optimal patient selection, based on pathology and anatomy, is being defined. Technically successful implantation requires adequate assessment of pathology and anatomy, and development and execution of novel and delicate procedures that resolve the pathology while minimizing morbidity and mortality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 22, 2008
Enrollment StartOct 1, 2001
Primary CompletionJul 1, 2013
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 17.8 years ago

Interventions

Endovascular Stent-graft repair of descending thoracic aortadevice

A TAG device will be used to repair the pathology in the thoracic aorta